Navigation Links
Cytochroma Announces Appointment of Peter Moldt to Board of Directors
Date:11/25/2009

MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on the Company's Board. The number of Board members remains unchanged at six members.

"We are very pleased to welcome Peter Moldt to the board and look forward to benefiting from his experience and guidance as Cytochroma continues to make progress in becoming a leading CKD-focused specialty pharmaceutical company," stated Alan Lewis, PhD, Chairman of Cytochroma's Board of Directors. "We are grateful for the advice that Ulrik Spork has provided to Cytochroma over the past year, and wish him well in the future."

Dr. Moldt has significant experience in corporate strategy, company operations, and drug development. He was most recently CEO of Curalogic A/S, a company he cofounded in 2004 and subsequently took public. Before Curalogic A/S, he was Chief Operating Officer of 7TM Pharma A/S, a company which he cofounded in 2000. Prior to 2000, Dr. Moldt spent 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Dr. Moldt holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy, and has been a post-doc with Yale University's Department of Organic Chemistry.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.

For more information about Cytochroma, please visit www.cytochroma.com.

SOURCE Cytochroma


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
6. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
7. Cytochroma announces appointment of Ulrik Spork to Board of Directors
8. Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for ... Dana-Farber Cancer Institute. The event is free and open to the public, but ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):